CD38 + BCMA dual-targeting CAR-T cells (Chinese PLA General Hospital)

CD38 + BCMA dual-targeting CAR-T cells is an investigational autologous chimeric antigen receptor (CAR) T-cell therapy developed by the Chinese PLA General Hospital for the treatment of relapsed or refractory multiple myeloma. The therapy involves engineering a patient's own T cells to simultaneously target two antigens highly expressed on malignant plasma cells: CD38 (ADP-ribosyl cyclase 1) and B-cell maturation antigen (BCMA; TNFRSF17). By targeting two distinct proteins, this dual-specific approach is designed to enhance the precision of tumor cell recognition and mitigate the risk of disease relapse due to antigen escape, a common mechanism of resistance in single-target CAR-T therapies. The product is currently being evaluated in Phase I/II clinical trials to determine its safety and efficacy in patients who have exhausted standard treatment options.

Other names

CD38 CAR-T cells + B-cell maturation antigen CAR-T cells-Chinese PLA General Hospital-multiple myelomaDual Specificity CD38 and BCMA CAR-T CellsCD38/BCMA dual CAR-T cellsCD38-BCMA CAR-TCD-38-BCMA CAR-TCD 38-BCMA CAR-T